Antiviral vaccines are essential for preventing epidemic disease; however, their production is often limited by low-yield manufacturing processes. Similarly, the development of gene therapies is constrained during the large-scale production of viral vectors, such as adeno-associated virus delivery platforms for gene transfer.
To speed the pace of these various areas of bioproduction, ATCC optimized three cell lines commonly used in virus manufacturing. ATCC used CRISPR-Cas9 gene-editing technology to develop STAT1- and BAX-knockout cell lines capable of producing high-titer viral stocks. These newly created cell lines can produce model clinical viruses and adeno-associated viruses at titers much higher than the parental cell lines, providing an efficient method for biopharmaceutical companies to increase production while reducing associated costs.
This white paper from ATCC describes the optimization of three cell lines approved for the production of viral vaccines with CRISPR-Cas9 gene-editing techniques to increase their viral production efficiency.
Offered Free by: ATCC
See All Resources from: ATCC